Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Social media companies and their respective algorithms have repeatedly been accused of fueling political polarization by promoting divisive content on their platforms. Now, two U.S. Senators have ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Follow 24/7 Wall St. on Google By Joey Frenette Published ...

Ever wondered how social media platforms decide how to fill our feeds? They use algorithms, of course, but how do these algorithms work? A series of corporate leaks over the past few years provides a ...

Community driven content discussing all aspects of software development from DevOps to design patterns. One of the Java platform’s enduring strengths has always been its ecosystem. Since the early ...

Learn how to use pattern-matching features in your Java programs, including pattern matching with switch statements, when clauses, sealed classes, and a preview of primitive type pattern matching in ...

Abstract: Distributed adaptive filtering has emerged as a critical methodology across diverse application domains, including wireless sensor networks, distributed signal processing, and intelligent ...

Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway to mid-2027. Exscientia, now part of ...